AtriCure delivered robust third-quarter performance with worldwide revenue reaching $134.3 million, a 15.8% increase year-over-year. The company significantly improved its net loss to $0.3 million and saw a substantial rise in Adjusted EBITDA to $17.8 million, demonstrating strong execution and increasing profitability.
Worldwide revenue grew by 15.8% year-over-year to $134.3 million, driven by strong product adoption.
Net loss improved significantly by $7.6 million year-over-year, reaching $0.3 million.
Adjusted EBITDA increased by $9.9 million year-over-year to $17.8 million, indicating enhanced profitability.
The company generated $30.1 million in cash during the third quarter, highlighting strong cash flow generation.
AtriCure has raised its financial outlook for the full year 2025, projecting higher revenue and Adjusted EBITDA, while maintaining expectations for cash flow generation.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance